Cell Therapy Products
Alofisel
TIGENIX
An allogeneic thérapie par cellules souches to treat complex perianal fistulas in patients with Crohn’s disease. Received EU marketing authorisation in March 2018.
Cartistem
MEDIPOST
A cellular therapeutic agent containing allogeneic human umbilical cord blood-derived mesenchymal stem cells, indicated for the treatment of knee cartilage defects such as traumatic articular cartilage, degenerative arthritis and rheumatoid arthritis. Approved for marketing by South Korea’s Ministry of Food and Drug Safety in January 2012.
Cellgram-AMI
FCB PHARMICELL
An autologous intracoronary bone marrow-derived mesenchymal stem cell injection for the treatment acute myocardial infarction. Approved for marketing by South Korea’s Food and Drug Administration in July 2011.
Cupistem
ANTEROGEN
An autologous adipose derived mesenchymal traitement des cellules souches to reduce inflammation and regenerate damage joint tissues, indicated for the treatment of Crohn’s fistula. Approved for marketing by South Korea’s Food and Drug Administration in July 2012.
CureSkin
S. BIOMEDICS
An autologous dermal fibroblast cell-based therapy approved in S. La Corée en 2010 for the treatment of depressed acne scars.
Holoclar
CHIESI FARMACEUTICI
Holoclar is a cell therapy based on autologous cultures of limbal stem cells. It regenerates a functional corneal epithelium allowing recovery of visual acuity. Holoclar is indicated for the treatment of moderate to severe limbal stem cell deficiency due to ocular burns. Granted conditional marketing authorization by the European Commission in February 2015.
Kaloderm
CETTE SCIENCES
An allogeneic cell therapy for deep second degree burns and diabetic foot ulcers. Homologué en S. Korea for burns in 2005 and diabetic foot ulcers in 2010.
KeraHeal
BIOSOLUTIONS
An autologous keratinocyte based cell therapy for the treatment of 2nd degree burns. Homologué en S. La Corée en 2006.
KeraHeal-Allo
BIOSOLUTIONS
A hydrogel-type allogeneic keratinocyte therapy product for the treatment of second-degree burns. Homologué en S. La Corée en 2015.
LaViv (Azficel-T)
FIBROCELL TECHNOLOGIES
LaViv is an autologous fibroblast-based cell therapy. Approuvé par les États-Unis. FDA in January 2011 for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.
Neuronata-r
CORESTEM
An autologous bone marrow mesenchymal thérapie par cellules souches approved in S. La Corée en 2014 for the treatment of ALS.
Queencell
ANTEROGEN
An autologous mesenchymal stem cell for the treatment of connective tissue disorders. Homologué en S. La Corée en 2010.
Rosmir
TEGO SCIENCE
Autologous cell therapy approved in S. La Corée en 2018 for the treatment of under eye wrinkles.
Spherox (formerly Chrondosphere)
CO.DON AG
A product containing spheroids of human autologous chondrocytes for use in cartilage defects. Commercialisé en Europe à partir de 2017; marketed in Germany since 2007.
Stemirac
NIPRO CORP
A mesenchymal thérapie par cellules souches approved in Japan in December 2018 for the treatment of spinal cord injury.
Stempeucel
STEMPEUTICS RESEARCH PVT
An ex-vivo cultured adult allogeneic mesenchymal stromal cell therapy for the treatment of Critical Limb Ischemia. Conditionally approved in India in 2017.
TEMCELL
JCR PHARMACEUTICALS CO LTD, LICENSEE OF MESOBLAST LTD
TEMCELL is an allogeneic mesenchymal stem cell product indicated for the treatment of acute radiation injury, chronic obstructive pulmonary disease, La maladie de Crohn, acute graft-versus-host disease, Type I diabetes and myocardial infarction. Approved by the Japanese Ministry of Health, Labour and Welfare for acute graft-versus-host disease in October 2015 and conditionally approved in Canada & New Zealand
